1、教育经历
(1) 2019/09-2022/06, 中国药科大学, 药物科学研究院,博士
(2) 2016/09-2019/06, 南京医科大学, 基础临床医学院,硕士
(3) 2010/09-2014/06, 中国药科大学, 药学, 学士
2、工作经历
(1)2022/06-至今, 中国药科大学, 药学院, 博士后
3、学术荣誉
2020/09,《江苏省研究生药学类学术创新论坛一等奖》
(1)肝脏疾病治疗靶标发现与药物研发
(2)新药临床前评价
1、学术获奖
2020/09,《江苏省研究生药学类学术创新论坛一等奖》
2、专利转化
(1) 2, 2-(4-羧基辛酰胺基)苯甲酸甲酯在制备治疗炎症性疾病药物中的应用 已授权 第三发明人 ZL 2018 1 1507809.8
(2) 5-氨基-1H-吡唑衍生物、制备方法及医药用途 已授权 第四发明人 ZL 2020 1 0396597.1
(3) 一种预防或治疗高尿酸血症和痛风的天然组合物 已完成申请权转让 10万 第二发明人 CN201810890997.0
1.Mengze Zhou, Weiwei Wang, Zhongkui Wang, Yilin Wang, Yifan Zhu, Zhiqian Lin, Sheng Tian, Yuan Huang, Qinghua Hu*, Huanqiu Li*. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y14R antagonists with anti-gout potential. Eur J Med Chem, 227: 113933.(IF:6.514)
2.Mengze Zhou, Weiwei Wang, Yehong Li, Qian Zhang, Hui Ji, Huanqiu Li*, Qinghua Hu*. The role of P2Y6R in cardiovascular diseases and recent development of P2Y6R antagonists. Drug Discov Today, 25(3):568-573. (IF: 7.321)
3.Liu CX#, Zhou MZ#, Jiang WJ et al. GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils. Front Immunol, 13:870183, 2022. (IF=7.561)
4.Shu-Min Ye#, Meng-Ze Zhou#, Wen-Jiao Jiang, Chun-Xiao Liu, Zhan-Wei Zhou, Min-Jie Sun*, Qing-Hua Hu*. Silencing of Gasdermin D by siRNA-Loaded PEI-Chol Lipopolymers Potently Relieves Acute Gouty Arthritis through Inhibiting Pyroptosis. Mol Pharm, 18 (2): 667-678. (IF:4.939)
5.Xinli Dong#, Mengze Zhou#, Yehong Li, Yuxin Li, Hui Ji, Qinghua Hu*. Cardiovascular Protective Effects of Plant Polysaccharides: A Review. Front Pharmacol, 12: 783641. (IF:5.81)
6.Mengze Zhou, Suning Li, Ling Song, Qinghua Hu*, Wentao Liu*.4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3. Phytomedicine, 42: 9-17.(IF: 3.61)